Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2018 - Issue
Submit an article Journal homepage
78
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers

Fabrizia Mariotti1 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy, [email protected]Correspondence[email protected]
,
Mirco Govoni1 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy, [email protected]
,
Germano Lucci1 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy, [email protected]
,
Debora Santoro1 Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy, [email protected]
&
Marie Anna Nandeuil2 Global Clinical Development, Chiesi S.A.S., Courbevoie, France
Pages 3399-3410 | Published online: 18 Oct 2018

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Federica Lo Bello, Philip M. Hansbro, Chantal Donovan, Irene Coppolino, Sharon Mumby, Ian M. Adcock & Gaetano Caramori. (2020) New drugs under development for COPD. Expert Opinion on Emerging Drugs 25:4, pages 419-431.
Read now
Polyxeni Ntontsi, Aggeliki Detta, Petros Bakakos, Stelios Loukides & Georgios Hillas. (2019) Experimental and investigational phosphodiesterase inhibitors in development for asthma. Expert Opinion on Investigational Drugs 28:3, pages 261-266.
Read now

Articles from other publishers (14)

Hoang Oanh Nguyen, Valentina Salvi, Laura Tiberio, Fabrizio Facchinetti, Mirco Govoni, Gino Villetti, Maurizio Civelli, Ilaria Barbazza, Carolina Gaudenzi, Mauro Passari, Tiziana Schioppa, Francesca Sozio, Annalisa Del Prete, Silvano Sozzani & Daniela Bosisio. (2022) The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation. Journal of Translational Medicine 20:1.
Crossref
Letizia Crocetti, Giuseppe Floresta, Agostino Cilibrizzi & Maria Paola Giovannoni. (2022) An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules 27:15, pages 4964.
Crossref
Isabel UWAGBOE, Ian M. ADCOCK, Federica LO BELLO, Gaetano CARAMORI & Sharon MUMBY. (2022) New drugs under development for COPD. Minerva Medica 113:3.
Crossref
Fabrizio Facchinetti, Maurizio Civelli, Dave Singh, Alberto Papi, Aida Emirova & Mirco Govoni. (2021) Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology 12.
Crossref
Dave Singh, Simon Lea & Alexander G. Mathioudakis. (2021) Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs 81:16, pages 1821-1830.
Crossref
Dave Singh, Michele Bassi, Deborah Balzano, Germano Lucci, Aida Emirova, Marie Anna Nandeuil, Gera Jellema, Ebenezer K. Afolabi, Brian Leaker, Oliver Kornmann, Kai Michael Beeh, Henrik Watz & Mirco Govoni. (2020) COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum. Journal of Cellular and Molecular Medicine 25:2, pages 905-918.
Crossref
Mirco Govoni, Michele Bassi, Stefano Vezzoli, Germano Lucci, Aida Emirova, Marie Anna Nandeuil, Stefano Petruzzelli, Gera L. Jellema, Ebenezer K. Afolabi, Brendan Colgan, Brian Leaker, Oliver Kornmann, Kai Michael Beeh, Henrik Watz & Dave Singh. (2020) Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respiratory Research 21:1.
Crossref
Yanaika Shari Sabogal Piñeros, Tamara Dekker, Barbara Smids, Christof J. Majoor, Lara Ravanetti, Gino Villetti, Maurizio Civelli, Fabrizio Facchinetti & René Lutter. (2020) Phosphodiesterase 4 inhibitors attenuate virus‐induced activation of eosinophils from asthmatics without affecting virus binding. Pharmacology Research & Perspectives 8:3.
Crossref
Brittany Woodby, Claudia Sticozzi, Erika Pambianchi, Gino Villetti, Maurizio Civelli, Giuseppe Valacchi & Fabrizio Facchinetti. (2020) The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways. Archives of Biochemistry and Biophysics 685, pages 108355.
Crossref
R Palova, J Adamcakova, D Mokra & J Mokry. (2020) Bronchial Asthma: Current Trends in Treatment. Acta Medica Martiniana 20:1, pages 9-17.
Crossref
Jonathan E. Phillips. (2020) Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. Frontiers in Pharmacology 11.
Crossref
D. Singh, M.A. Nandeuil, C. Pigeon-Francisco, A. Emirova, D. Santoro, S. Biondaro, G. Cohuet, M. Govoni, A. Bachiri & S. Petruzzelli. (2020) Étude de recherche de dose PIONEER : efficacité et tolérance du CHF6001, un nouvel inhibiteur de PDE4 par voie inhalée. Revue des Maladies Respiratoires Actualités 12:1, pages 22.
Crossref
Fabio F. Stellari, Angelo Sala, Francesca Ruscitti, Carola Buccellati, Andrew Allen, Patrizia Risé, Maurizio Civelli & Gino Villetti. (2019) CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice. Frontiers in Pharmacology 10.
Crossref
Haoxiao Zuo, Isabella Cattani-Cavalieri, Nshunge Musheshe, Viacheslav O. Nikolaev & Martina Schmidt. (2019) Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacology & Therapeutics 197, pages 225-242.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.